Esperion Therapeutics, listed as (NASDAQ:ESPR), is a pharmaceutical company focused on developing and commercializing therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). The company aims to provide alternatives for patients who are intolerant to statins. Esperion's competitors include Amgen and Regeneron, which also offer cholesterol-lowering treatments.
On March 10, 2026, Esperion reported earnings per share (EPS) of $0.21, slightly below the estimated $0.23. This represents a negative surprise of 5.38%, as highlighted by Zacks. However, this is an improvement from a loss of $0.10 per share in the same quarter last year. In the previous quarter, Esperion reported a larger-than-expected loss of $0.16 per share, missing the anticipated loss of $0.09.
Despite the earnings miss, Esperion's revenue for the quarter ending December 2025 was $168.4 million, surpassing the estimated $166.1 million. This marks a 144% increase from the $69.11 million reported in the same period the previous year. The company has consistently exceeded consensus revenue estimates in each of the last four quarters, demonstrating strong revenue growth.
For the fiscal year 2025, Esperion's total revenue increased by 21% year-over-year, reaching $403.1 million. In the U.S., net product revenue rose by 38% year-over-year to $159.6 million. In the fourth quarter of 2025, U.S. net product revenue grew by approximately 38% year-over-year to $43.7 million. Retail prescription equivalents also increased by 34% year-over-year and 11.3% quarter-over-quarter.
Esperion has announced an agreement to acquire Corstasis Therapeutics, aiming to expand its cardiovascular franchise. The acquisition includes Enbumyst, a bumetanide nasal spray. Despite the company's strategic advancements, it faces challenges with a negative enterprise value to operating cash flow ratio of -6.27, indicating difficulties in generating positive cash flow.
